Table 2.
Domain scores (%) of the 16 clinical practice guidelines assessed using the AGREE-II instrument.
| Domain | AASLD (2023) | AGA (2022) | APASAL (2017) | ASCO (2024) | Canada (2021) | Chinese (2023) | ESAL (2018) | ESMO (2021) | Japan (2023) | Korea (2022) | NCCN (2024) | Taiwan (2024) | APPLE (2020) | BCLC (2022) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Domain 1: scope and purpose | 91.67% | 92.22% | 83.33% | 100.00% | 98.89% | 88.89%/ | 100.00% | 67.78% | 94.44% | 100.00% | 81.11% | 94.44% | 95.56% | 72.22% |
| Domain 2: stakeholder involvement | 69.44% | 83.33% | 61.11% | 94.44% | 71.11% | 58.33%/ | 78.89% | 51.11% | 80.56% | 76.67% | 61.11% | 71.30% | 63.33% | 62.22% |
| Domain 3: rigor of development | 67.71% | 88.75% | 76.25% | 96.25% | 70.42% | 57.99% | 88.75% | 68.75% | 97.92% | 93.75% | 88.54% | 97.92% | 65.42% | 67.08% |
| Domain 4: clarity of presentation | 100.00% | 95.56% | 95.56% | 97.78% | 84.44% | 80.56% | 95.56% | 96.67% | 100.00%/ | 100.00% | 97.22% | 97.22% | 91.11% | 100.00% |
| Domain 5: applicability | 83.33% | 73.33% | 78.33% | 80.0% | 78.33% | 77.08% | 86.67% | 85.00% | 100.00% | 80.00% | 77.50% | 79.86% | 73.33% | 74.17% |
| Domain 6: editorial independence | 100.00% | 91.67% | 83.33% | 91.67% | 91.67% | 100.00% | 93.33% | 80.00% | 100.00% | 100.00% | 100.00% | 100.00% | 86.67% | 88.33% |
| Overall (range 1~7) | 6.09 | 6.21 | 5.72 | 6.78 | 5.76 | 5.33 | 6.39 | 5.43 | 6.80 | 6.37 | 5.80 | 6.41 | 5.54 | 5.47 |
AASLD, American Association for the Study of Liver Diseases; AGA, the American Gastroenterological Association; APASL, The Asian Pacific Association for the Study of the Liver; APPLE, the Asia-Pacific Primary Liver Cancer Expert; ASCO, American Society of Clinical Oncology; BCLC, Barcelona Clinic Liver Cancer; EASL, European Association for the Study of the Liver; ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network.